|
|
|
市場調査レポート
アポトーシス療法市場
APOPTOSIS-BASED THERAPEUTICS: CELL DEATH TO MARKET BIRTH
| 発行 |
Theta Reports (PJB Medical Publications, Inc.) |
| 出版日 |
2004年05月 |
商品コード |
19870 |
| ページ情報 |
英文 |
| 価格 |
|
|
当商品の販売は、2011年07月19日を持ちまして終了しました。
The market for therapeutic apoptosis modulators is currently only emerging.
However, over the five-year time course of this analysis, significant progress
is anticipated with respect to the realization of the incredible potential
offered by certain apoptosis modulators.
Theta' s report focuses on a complete description of advances made in
developing and bringing therapeutic apoptosis modulators to markets worldwide
and includes an analysis of probable future developments in the treatment of
variety of diseases and conditions such as, cancer, cardiovascular disease,
autoimmune diseases, infectious diseases, Alzheimer' s disease, Parkinson' s
disease, HIV/AIDS, and organ transplant rejection.
Major therapeutic targets of apoptosis-based compounds discussed in the
report include:
- Caspase activators and inhibitors
- Bcl-2 modulators
- p53 modulators
- Inhibitors of apoptosis proteins (IAPs)
- Protein kinase pathway modulators
- Mixed lineage kinase inhibitor
- Multiple signal transduction regulators
Table of Contents
- 1 Executive Summary
- 1.1 Scope and Objectives of the Report
- 1.2 Methodology
- 1.3 Emerging World Market for Therapeutic Apoptosis Modulators
- 2 Introduction and Overview
- 2.1 Definition of Apoptosis
- 2.2 Apoptotic Stimuli and Targets
- 2.3 Molecular Pathways of Apoptosis
- 2.3.1 Bcl-2 Proteins
- 2.3.2 Caspases
- 2.3.3 Death Receptors
- 2.3.4 Inhibitors of Apoptosis Protein (IAPs)
- 2.3.5 Apoptotic Physiological Regulation Summary
- 2.4 Apoptosis-associated Diseases and Conditions
- 2.4.1 Cancer
- 2.4.2 Cardiovascular Disease
- 2.4.3 Rheumatoid Arthritis
- 2.4.4 Multiple Sclerosis
- 2.4.5 Thyroid Disease
- 2.4.6 HIV Infection
- 2.4.7 Sepsis and Multiple Organ Dysfunction Syndrome (MODS)
- 2.4.8 Alzheimer's Disease
- 2.4.9 Parkinson’s Disease
- 2.4.10 Organ Transplant Rejection
- 3 Technological Issues for Apoptosis based Therapeutics
- 3.1 Key Drug Discovery Technologies
- 3.1.1 High Throughput Screening
- 3.1.2 Sequential High Throughput Screening
- 3.1.3 Combinatorial Chemistry and Parallel Synthesis
- 3.2 Target Identification and Validation
- 3.2.1 Genomics/Proteomics
- 3.2.2 Structural Biology
- 3.3 Compound Identification
- 3.3.1 Antisense
- 3.3.2 Recombinant Proteins
- 3.3.3 Small Molecule Mimetics
- 4 Apoptosis-based Drugs in Development
- 4.1 Caspase Activators and Inhibitors
- 4.1.1 IDN-6734
- 4.1.2 IDN-6556
- 4.1.3 MX1122
- 4.1.4 MX1013
- 4.1.5 VX-799
- 4.1.6 Pralnacasan (VX-740)
- 4.1.7 Executioner Caspases
- 4.2 Bcl-2 Modulators
- 4.2.1 Genasense
- 4.2.2 HA14-1
- 4.3 p53 Modulators
- 4.3.1 Advexin
- 4.3.2 INGN 241
- 4.3.3 INGN 251
- 4.3.4 SCH58500
- 4.3.5 ONYX-015
- 4.4 Inhibitors of Apoptosis Protein (IAPs)
- 4.5 Protein Kinase Pathway Modulators
- 4.5.1 Alkyl-lysophosphocholines: Perifosine
- 4.5.2 Bcr-Abl Tyrosine Kinase Inhibitor: Gleevec
- 4.5.3 Stress-Activated Protein Kinase (SAPK) Activator: TELCYTA
- 4.6 Mixed Lineage Kinase (MLK) Inhibitor: CEP-1347
- 4.7 Multiple Signal Transduction Regulators
- 4.7.1 Phenoxodiol
- 4.7.2 CO-501 (-lapachone)
- 4.8 TNF-Related Apoptosis Inducing Ligand (TRAIL)
- 4.9 Lysophosphatidic Acid Acyltransferase- (LPAAT-)
- 4.10 Nicotinic Acetylcholine Receptor (nAChR) Agonist
- 4.11 Heat Shock Protein 27 (Hsp27)
- 4.12 Factor 5A
- 4.13 Miscellaneous Mechanisms of Action
- 4.13.1 Angiogenesis Modulators
- 4.13.2 Antibodies
- 4.13.3 Antisense Agents
- 4.13.4 Proteasome Inhibitors
- 4.13.5 Specific Recombinant Antigen: MP4
- 4.13.6 Selective Apoptotic Anti-Neoplastic Drugs (SAANDs)
- 5 World Market Analysis
- 5.1 Market Overview
- 5.1.1 Market Definition
- 5.1.2 Major Drug Products
- 5.1.3 Competitor Companies
- 5.1.4 Costs of Drug Development
- 5.2 Total Emerging World Market Size and Forecasts
- 5.2.1 Total Global Market, 2003-2008
- 5.2.2 Total U.S. Market Size and Forecasts, 2003-2008
- 5.2.3 Total Western European Market Size and Forecasts, 2003-2008
- 5.2.4 Total Japanese Market Size and Forecasts, 2003-2008
- 5.2.5 Total Rest of World Market Size and Forecasts, 2003-2008
- 5.2.6 Geographic Shares of Total World Market, 2008
- 5.3 Caspase Activators and Inhibitors
- 5.4 Bcl-2 Modulators
- 5.4.1 Overall World Market
- 5.4.2 U.S. Market Size and Forecasts, 2003-2008
- 5.4.3 Western European Market Size and Forecasts, 2003-2008
- 5.4.4 Japanese Market Size and Forecasts, 2003-2008
- 5.4.5 Rest of World Market Size and Forecasts, 2003-2008
- 5.4.6 Geographic Market Shares, 2008
- 5.4.7 Analysis of Potential Competitors
- 5.5 TP53 Modulators
- 5.5.1 Overall World Market
- 5.5.2 U.S. Market Size and Forecasts, 2003-2008
- 5.5.3 Western European Market Size and Forecasts, 2003-2008
- 5.5.4 Japanese Market Size and Forecasts, 2003-2008
- 5.5.5 Rest of World Market Size and Forecasts, 2003-2008
- 5.5.6 Geographic Market Shares, 2008
- 5.5.7 Analysis of Potential Competitors
- 5.6 Mixed Lineage Kinase (MLK) Inhibitors
- 5.6.1 Overall World Market
- 5.6.2 Geographic Regional Markets, 2008
- 5.6.3 Geographic Market Shares, 2008
- 5.6.4 Analysis of Potential Competitors
- 5.7 Proteasome Inhibitors
- 5.7.1 Overall World Market
- 5.7.2 U.S. Market Size and Forecasts, 2003-2008
- 5.7.3 Western European Market Size and Forecasts, 2003-2008
- 5.7.4 Japanese Market Size and Forecasts, 2003-2008
- 5.7.5 Rest of World Market Size and Forecasts, 2003-2008
- 5.7.6 Geographic Market Shares, 2008
- 5.7.7 Analysis of Potential Competitors
- 5.8 SAPK Activator: TELCYTA
- 5.8.1 Overall World Market
- 5.8.2 Geographic Regional Markets, 2008
- 5.8.3 Geographic Market Shares, 2008
- 5.8.4 Analysis of Potential Competitors
- 5.9 Selective Apoptotic Anti-Neoplastic Drugs (SAANDs)
- 5.9.1 Overall World Market
- 5.9.2 Geographic Regional Markets, 2008
- 5.9.3 Geographic Market Shares, 2008
- 5.9.4 Analysis of Potential Competitors
- 6 Company Briefs
- 6.1 Access Oncology Inc.
- 6.2 Aegera Therapeutics Inc.
- 6.3 Alexion Pharmaceuticals Inc.
- 6.4 Amgen Inc.
- 6.5 Antisoma plc
- 6.6 Applied Molecular Evolution Inc.
- 6.7 Aventis Pharmaceuticals Inc.
- 6.8 AVI BioPharma Inc.
- 6.9 Celgene Corp.
- 6.10 Cell Therapeutics Inc.
- 6.11 Cephalon Inc.
- 6.12 Cyclacel Ltd.
- 6.13 Cyclis Pharmaceuticals Inc.
- 6.14 Dendreon Corp.
- 6.15 Endovasc Inc.
- 6.16 EntreMed Inc.
- 6.17 Gemin X Biotechnologies
- 6.18 Genentech Inc.
- 6.19 Genmab A/S
- 6.20 Genta Inc.
- 6.21 Hoffman-La Roche
- 6.22 Human Genome Sciences, Inc.
- 6.23 Hybridon Inc.
- 6.24 Idun Pharmaceuticals Inc.
- 6.25 ILEX Oncology, Inc.
- 6.26 Introgen Therapeutics, Inc.
- 6.27 ISIS Pharmaceuticals, Inc.
- 6.28 Keryx Biopharmaceuticals Inc.
- 6.29 Ligand Pharmaceuticals
- 6.30 Marshall Edwards Inc.
- 6.31 Maxim Pharmaceuticals
- 6.32 Millennium Pharmaceuticals Inc.
- 6.33 Novartis AG
- 6.34 Onyx Pharmaceuticals, Inc.
- 6.35 OSI Pharmaceuticals, Inc.
- 6.36 OXiGENE, Inc.
- 6.37 Peregrine Pharmaceuticals Inc.
- 6.38 Pharmos Corp.
- 6.39 Phytomedics, Inc.
- 6.40 Protein Design Labs Inc.
- 6.41 Schering-Plough Corp.
- 6.42 Senesco Technologies, Inc.
- 6.43 SuperGen, Inc.
- 6.44 Targeted Genetics Corp.
- 6.45 Telik Inc.
- 6.46 Vertex Pharmaceuticals Inc.
- 6.47 Xenova Group plc
- 6.48 Zentaris AG
- 7 Company Directory
List of Tables
- Table 5-1 Companies Developing Apoptosis-based Therapeutics
- Table 5-2 Total World Market for Novel Apoptosis-based Therapeutics
2003-2008
- Table 5-3 Total U.S. Market for Novel Apoptosis-based Therapeutics
2003-2008
- Table 5-4 Total Western European Market for Novel Apoptosis-based
Therapeutics 2003-2008
- Table 5-5 Total Japanese Market for Novel Apoptosis-based Therapeutics
2003-2008
- Table 5-6 Total Rest of World Market for Novel Apoptosis-based
Therapeutics 2003-2008
- Table 5-7 Total World Market Shares for Novel Apoptosis-based Therapeutics
by Geographic Region 2008
- Table 5-8 World Market for Bcl-2 Modulators 2003-2008
- Table 5-9 U.S. Market for Bcl-2 Modulators 2003-2008
- Table 5-10 Western European Market for Bcl-2 Modulators 2003-2008
- Table 5-11 Japanese Market for Bcl-2 Modulators 2003-2008
- Table 5-12 Rest of World Market for Bcl-2 Modulators 2003-2008
- Table 5-13 Market Shares for Bcl-2 Modulators by Geographic Region 2008
- Table 5-14 World Market for TP53 Modulators 2003-2008
- Table 5-15 U.S. Market for TP53 Modulators 2003-2008
- Table 5-16 Western European Market for TP53 Modulators 2003-2008
- Table 5-17 Japanese Market for TP53 Modulators 2003-2008
- Table 5-18 Rest of World Market for TP53 Modulators 2003-2008
- Table 5-19 Market Shares for TP53 Modulators by Geographic Region 2008
- Table 5-20 Market for Mixed Lineage Kinase Inhibitors by Geographic Region
2008
- Table 5-21 Market Shares for Mixed Lineage Kinase Inhibitors by Geographic
Region 2008
- Table 5-22 World Market for Mixed Lineage Kinase Inhibitors 2003-2008
- Table 5-23 U.S. Market for Mixed Lineage Kinase Inhibitors 2003-2008
- Table 5-24 Western European Market for Mixed Lineage Kinase Inhibitors
2003-2008
- Table 5-25 Japanese Market for Mixed Lineage Kinase Inhibitors 2003-2008
- Table 5-26 Rest of World Market for Mixed Lineage Kinase Inhibitors
2003-2008
- Table 5-27 Market Shares for Mixed Lineage Kinase Inhibitors by Geographic
Region 2008
- Table 5-28 Market for TELCYTA by Geographic Region 2008
- Table 5-29 Market Shares for TELCYTA by Geographic Region 2008
- Table 5-30 Market for SAANDs by Geographic Region 2008
- Table 5-31 Market Shares for SAANDs by Geographic Region 2008
List of Figurs
- Figure 5-1 Total World Market for Novel Apoptosis-based Therapeutics
2003-2008
- Figure 5-2 Total U.S. Market for Novel Apoptosis-based Therapeutics
2003-2008
- Figure 5-3 Total Western European Market for Novel Apoptosis-based
Therapeutics 2003-2008
- Figure 5-4 Total Japanese Market for Novel Apoptosis-based Therapeutics
2003-2008
- Figure 5-5 Total Rest of World Market for Novel Apoptosis-based
Therapeutics 2003-2008
- Figure 5-6 Total World Market Shares for Novel Apoptosis-based
Therapeutics by Geographic Region 2008
- Figure 5-7 World Market for Bcl-2 Modulators 2003-2008
- Figure 5-8 U.S. Market for Bcl-2 Modulators 2003-2008.
- Figure 5-9 Western European Market for Bcl-2 Modulators 2003-2008
- Figure 5-10 Japanese Market for Bcl-2 Modulators 2003-2008.
- Figure 5-11 Rest of World Market for Bcl-2 Modulators 2003-2008
- Figure 5-12 Market Shares for Bcl-2 Modulators by Geographic Region 2008 .
- Figure 5-13 World Market for TP53 Modulators 2003-2008
- Figure 5-14 U.S. Market for TP53 Modulators 2003-2008
- Figure 5-15 Western European Market for TP53 Modulators 2003-2008
- Figure 5-16 Japanese Market for TP53 Modulators 2003-2008.
- Figure 5-17 Rest of World Market for TP53 Modulators 2003-2008
- Figure 5-18 Market Shares for TP53 Modulators by Geographic Region 2008 .
- Figure 5-19 Market for Mixed Lineage Kinase Inhibitors by Geographic
Region 2008
- Figure 5-20 Market Shares for Mixed Lineage Kinase Inhibitors by
Geographic Region 2008
- Figure 5-21 World Market for Mixed Lineage Kinase Inhibitors 2003-2008.
- Figure 5-22 U.S. Market for Mixed Lineage Kinase Inhibitors 2003-2008
- Figure 5-23 Western European Market for Mixed Lineage Kinase Inhibitors
2003-2008
- Figure 5-24Japanese Market for Mixed Lineage Kinase Inhibitors 2003-2008.
- Figure 5-25 Rest of World Market for Mixed Lineage Kinase Inhibitors
2003-2008 .
- Figure 5-26 Market Shares for Mixed Lineage Kinase Inhibitors by
Geographic Region 2008
- Figure 5-27 Market for TELCYTA by Geographic Region 2008 .
- Figure 5-28 Market Shares for TELCYTA by Geographic Region 2008
- Figure 5-29 Market for SAANDs by Geographic Region 2008 .
- Figure 5-30 Market Shares for SAANDs by Geographic Region 2008 .
|
 |
